BG-C137

Phase 1Small molecule

BBeOne Medicines

BG-C137 is one of 93 small molecule programs targeting Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Advanced Solid TumorRecruiting

GrowthActive, not recruiting

Solid TumorPhase 1

Recruiting

Advanced Solid TumorPhase 1

Recruiting

GrowthPhase 1

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Preclinical

35 2

Lovenox

Sanofi

Preclinical

2 3

Lenvima

Eisai

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Aricept

Eisai

Preclinical

1 6

Herceptin

OOrganon and Co

Preclinical

4 7

Somavaratan

Glucophage

2 9

EGRIFTA WR

TTheratechnologies

Preclinical

2 10

Neupogen

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Solid Tumor

NCT06625593

Clinical

Trials by Indication[1]

Solid Tumor1 trial

A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors

Recruiting·BBeOne Medicines·Phase 1·NCT06625593·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BG-C137. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BG-C137 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BG-C137. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeOne Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBeOne Medicines

BG-C137

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News